Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone

Human Reproduction

Volumn 16, Issue 12, 2001, Pages 2570-2577

  Behre, H M ^a,b   Kliesch, S ^a   Lemcke, B ^a   Von Eckardstein, S ^a   Nieschlag, E ^a  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

19 Nortestosterone; GnRH antagonist; Gonadotrophins; Male contraception; Spermatogenesis

Indexed keywords

ANDROGEN; CETRORELIX; ESTRADIOL; FOLLITROPIN; GONADORELIN ANTAGONIST; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INHIBIN B; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; NANDROLONE 4 HEXYLOXYHYDROCINNAMATE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; AZOOSPERMIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ERYTHEMA; FOLLITROPIN BLOOD LEVEL; GONADOTROPIN BLOOD LEVEL; HORMONAL CONTRACEPTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; MAINTENANCE THERAPY; MALE; METABOLIC INHIBITION; NORMAL HUMAN; PROSTATE; PROTEIN BLOOD LEVEL; SEX HORMONE DETERMINATION; SEXUAL FUNCTION; SPERMATOGENESIS; STIMULATION; TESTIS SIZE; TESTOSTERONE BLOOD LEVEL;

PRIMATES;

EID: 0035657262     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.12.2570     Document Type: Article

References (32)

1. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens
2. GnRH agonist/antagonist-androgen combinations for male contraception
3. Objective measurement of testicular volume by ultrasonography: Evaluation of the technique and comparison with orchidometer estimates
4. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception
5. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched controls
6. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulation hormone, and testosterone in normal men
7. Clinical trial of a non-injectable male contraceptive: Transdermal testosterone and oral levonorgestrel
8. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia
9. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: A potential alternative to testosterone for androgen replacement and male contraception
10. Serum inhibin B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples
11. Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men
12. Oestradiol enhances testosterone-induced suppression of human spermatogenesis
13. Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback
14. Differential regulation of gonadotropin secretion by testosterone in the human male: Absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion
15. The cynomolgus monkey prostate under physiological and hypogonadal conditions: An ultrasonographic study
16. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception
17. Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (anadur) for male fertility regulation
18. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women
19. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-esticular axis in normal men
20. Is high dosage testosterone an effective male contraceptive agent?
21. Male contribution to contraception
22. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido
23. Complete suppression of spermatogenesis by co-administration of a GnRH antagonist plus a physiologic dose of testosterone
24. Dihydrotestosterone: A rationale for its use as a non-aromatizable androgen replacement therapeutic agent
25. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone
26. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate
27. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha-reduced derivatives to the androgen receptor and to other androgen-binding proteins: A suggested role of 5alpha-reductive steroid metabolism in the dissociation of 'myotropic' and 'androgenic' activities of 19-nortestosterone
28. Estrogen deficiency in men is a challenge for both the hypothalamus and pituitary
29. Can testosterone alone maintain the GnRH antagonist-induced suppression of spermatogenesis in the non-human primate?
30. Contraceptive efficacy of testosterone-induced azoospermia in normal men
31. Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies
32. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men